ClinicalTrials.gg

Program

anifrolumab

Also written as “Anifrolumab”, “MEDI-546” and “Anifrolumab (blinded)”.

Its studies are mostly in Lupus Erythematosus, Systemic · Lupus Nephritis · Scleroderma, Systemic · Lupus Erythematosus, Cutaneous · Dermatomyositis, led by AstraZeneca.

Furthest: phase 4, since Sep 10, 202425 company-led studies, 12 open or runningNext primary completion: Jan 6, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca2512 open or runningphase 4since Sep 10, 2024Jun 29, 2009Jan 6, 2027phase 3 · NCT05925803

Also a collaborator on its studies: icon-plc, parexel, ppd-development-lp, iqvia-pty-ltd and pra-health-sciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Jun 29, 2009.

  1. May 4, 2021Phase 3 study in Lupus Erythematosus, SystemicNCT04877691 · 367 enrolled · United States, Argentina, Bulgaria and more
  2. Jun 30, 2021Phase 1 study in Lupus Erythematosus, SystemicNCT05001698 · 15 enrolled · China
  3. Nov 17, 2021Phase 3 study in Lupus NephritisNCT05138133 · 363 enrolled · United States, Argentina, Belgium and more
  4. Apr 18, 2023Phase 3 study in Lupus Erythematosus, SystemicNCT05835310 · 100 planned · United States, Argentina, Brazil and more
  5. Jun 2, 2023Phase 3 study in Scleroderma, SystemicNCT05925803 · 314 enrolled · United States, Austria, Belgium and more
  6. Aug 1, 2023Phase 3 study in Lupus Erythematosus, CutaneousNCT06015737 · 339 enrolled · United States, Argentina, Australia and more
  7. Sep 28, 2023Phase 3 study in DermatomyositisNCT06455449 · 240 planned · United States, Argentina, Australia and more
  8. Sep 4, 2024Phase 1 study in Healthy VolunteersNCT06662123 · 24 enrolled · China
  9. Sep 10, 2024Phase 4 study in Lupus Erythematosus, SystemicNCT06594068 · 16 planned · United States
  10. Feb 2, 2026Phase 3 study in Lupus Erythematosus, SystemicNCT07430306 · 245 planned · United States, Canada, France and more
  11. Jun 2, 2026Phase 2 study in Lupus Erythematosus, SystemicNCT07630714 · 24 planned · Australia, Belgium, Chile and more
  12. Jun 23, 2026Phase 3 study in Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus ErythematosusNCT07691970 · 1,072 planned · United States, Argentina, Australia and more
  13. Jun 30, 2026Phase 1 study in Lupus Erythematosus, SystemicNCT07688980 · 92 planned
  14. Jul 21, 2026Phase 3 study in Lupus Erythematosus, SystemicNCT07751848 · 417 planned · China

Ahead

  1. Nov 2, 2026Primary completion: phase 3 study in Lupus Erythematosus, CutaneousNCT06015737
  2. Jan 6, 2027Primary completion: phase 3 study in Scleroderma, SystemicNCT05925803
  3. Feb 23, 2027Primary completion: phase 3 study in Lupus NephritisNCT05138133
  4. Aug 31, 2027Primary completion: phase 4 study in Lupus Erythematosus, SystemicNCT06594068

TargetBeta

IFNAR1 →read by rule
“Interferon-alpha/beta receptor alpha chain antagonist”ChEMBL 37, by rule

Other programs on IFNAR1

ProgramCompanyFurthest phaseStudies
peginterferon alfa-2aruleHoffmann-La Rochephase 4100
Interferon beta-1aruleBiogenphase 460
peginterferon alfa-2bruleMerckphase 456
SHR-2173Jiangsu HengRui Medicinephase 28

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07751848Lupus Erythematosus, Systemic · China3RecruitingAug 25, 2028417
NCT07688980Lupus Erythematosus, Systemic1Not yet recruitingApr 13, 202992
NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus · United States, Argentina, Australia and more3RecruitingDec 30, 20321,072
NCT07630714Lupus Erythematosus, Systemic · Australia, Belgium, Chile and more2RecruitingSep 2, 203024
NCT07430306Lupus Erythematosus, Systemic · United States, Canada, France and more3RecruitingJan 26, 2029245
NCT06594068Lupus Erythematosus, Systemic · United States4RecruitingAug 31, 202716
NCT06662123Healthy Volunteers · China1CompletedJan 10, 202524
NCT06455449Dermatomyositis · United States, Argentina, Australia and more3RecruitingJan 10, 2028240
NCT06015737Lupus Erythematosus, Cutaneous · United States, Argentina, Australia and more3Active, not recruitingNov 2, 2026339
NCT05925803Scleroderma, Systemic · United States, Austria, Belgium and more3Active, not recruitingJan 6, 2027314
NCT05835310Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more3RecruitingOct 5, 2028100
NCT05138133Lupus Nephritis · United States, Argentina, Belgium and more3Active, not recruitingFeb 23, 2027363
NCT05001698Lupus Erythematosus, Systemic · China1CompletedJun 2, 202215
NCT04877691Lupus Erythematosus, Systemic · United States, Argentina, Bulgaria and more3Active, not recruitingAug 22, 2025367
NCT04931563Active Systemic Lupus Erythematosus · China, Hong Kong, Philippines and more3CompletedApr 7, 2025277
NCT02962960Lupus Erythematosus, Systemic · United States, Hungary, Korea, Republic of and more2CompletedJan 22, 201836
NCT02794285Connective Tissue Diseases · United States, Argentina, Australia and more3CompletedDec 21, 2021559
NCT02601625Safety · United States1CompletedMay 25, 201630
NCT02547922Lupus Nephritis · United States, Argentina, Australia and more2CompletedNov 26, 2019147
NCT02446912Active Systemic Lupus Erythematosus · United States, Argentina, Australia and more3CompletedJul 17, 2018460
NCT02446899Active Systemic Lupus Erythematosus · United States, Argentina, Belgium and more3CompletedSep 27, 2018373
NCT01753193Lupus Erythematosus, Systemic · United States, Brazil, Bulgaria and more2CompletedJul 18, 2018218
NCT01559090Lupus Erythematosus, Systemic · Japan2CompletedAug 19, 201417
NCT01438489Lupus Erythematosus, Systemic · United States, Brazil, Bulgaria and more2CompletedApr 2015626
NCT00930683Scleroderma, Diffuse · United States1CompletedMay 201034

How it is read

Names in the registry

  • “Anifrolumab”, 18 entries
  • “MEDI-546”, 12 entries
  • “Anifrolumab (blinded)”, 2 entries
  • “Anifrolumab (unblinded, open label)”, 2 entries
  • “Anifrolumab + APFS”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.